Immunotherapy with serum obtained from immunized volunteers with Escherichia Coli J5 vaccine was shown to decrease the mortality from Gram-negative shock. We analyzed the effect of anti-J5 plasma on the course and mortality of severe infectious purpura. Patients with a clinical diagnosis of sepsis wiwth purpuric lesions were enrolled if they were in shock. They received either anti-J5 plasma or control plasma. Before the administration of the plasma, 6 hours after and after 5 days of evolution, serum levels of anti-J5 antibodies, tumor necrosis factor alpha (TNF), interleukin-6 (IL-6) and elastase-al-antiprotease complexes were determined. 73 patients were randomized, 40 in the anti-J5 and 33 in the control group. Clinical and biological risk factors were similar in the two groups. However, TNF serum concentrations were 974±173pg/ml versus 473±85pg/ml, (p=0.023) and IL-6 serum concentrations were 129±45 versus 19±5ng/ml, (p=0.005) in the control group and in the treated group respectively. The duration of hypotension, of vasopressor therapy and of respiratory assistance and the occurrence of systemic complications were similar in the 2 groups. The mortality rate was 36 % in the control group and 25% in the treated group (p=0.317), (risk ratio:0.58;95% confidence interval:0.19-1.79). This trend disappeared after correction for imbalances at randomization using a logistic regression model. Anti-J5 plasma did not change the course and the mortality of severe infectious purpura in children.
About this article
Cite this article
Girardin, E., Baumgartner, JD., Beaufils, F. et al. 118 TREATMENT OF SEVERE INFECTIOUS PURPURA IN CHILDREN WILL HUMAN PLASMA FROM DONORS IMMUNIZED WITH ESCHERICHILA COLI JS: A PROSPECTIVE, DOUBLE BLIND STUDY. Pediatr Res 30, 647 (1991). https://doi.org/10.1203/00006450-199112000-00148